News | ASTRO | November 01, 2019

ASTRO supports nomination of Stephen Hahn, M.D., FASTRO, to lead U.S. FDA

Hahn has served on the ASTRO Board of Directors and has broad knowledge as a clinician, researcher, educator and administrative leader

Stephen Hahn, M.D., FASTRO

Stephen Hahn, M.D., FASTRO

November 1, 2019 — The American Society for Radiation Oncology (ASTRO) today expressed strong support for the nomination of radiation oncologist Stephen Hahn, M.D., FASTRO, as Commissioner of the Food and Drug Administration (FDA). Hahn served on the ASTRO Board of Directors from 2014 to 2018. ASTRO urges the Senate to swiftly confirm the nomination announced today by President Donald Trump.

Hahn has broad knowledge as a clinician, researcher, educator and administrative leader, and he previously obtained the rank of commander in the U.S. Public Health Service. He is well-versed on the drug, biologic and device development pipeline, demonstrated by his role in developing multiple medical products. His clinical expertise and training in internal medicine, medical oncology and radiation oncology, as well as his international recognition in treating lung cancer give him the ability to tackle some of the toughest issues faced by the FDA.

Several members of ASTRO's leadership who have worked with Hahn shared their support of his nomination:

"I have known Dr. Hahn for many years and have served with him in numerous capacities.  He possesses the qualities needed to successfully lead the FDA … intelligence, medical and scientific expertise, an engaging style and a clear sense of how to get to the right answer, particularly in complicated situations.”

Theodore L. DeWeese, M.D., FASTRO; Chair, ASTRO Board of Directors 2019-2020; Vice Dean for Clinical Affairs, Sidney Kimmel Professor and Director of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine

"During his tenure on the ASTRO Board, Dr. Hahn always brought insightful questions to our deliberations. He takes the time to listen to all sides before he reaches a decision, which will be important in this new role. I also don't know that I have ever seen anyone who can cover as much ground as he can cover. His depth of knowledge will allow him to accomplish the many tasks ahead as FDA Commissioner.”

Laura I. Thevenot; Chief Executive Officer, ASTRO

"Dr. Hahn is a brilliant physician leader with the highest levels of integrity and problem-solving talent.  With a background in radiation oncology and medical oncology, he is uniquely positioned to advance the crucial work of the FDA.”

Ronald Ennis, M.D., FASTRO; Government Relations Council Chair, ASTRO Board of Directors 2019-2020; Associate Professor of Radiation Oncology, Icahn School of Medicine at Mount Sinai

 

ASTRO previously expressed its support of Dr. Hahn after news reports in September suggested he was being considered for the FDA leadership post. That statement, from then-ASTRO Chair Paul Harari, M.D., FASTRO, noted how Dr. Hahn's clinical experience could translate into success leading the FDA:

"A culture of safety is woven into the fabric of radiation oncology, making Dr. Hahn expertly suited to further FDA’s mission of protecting the public health. At the same time, Dr. Hahn’s experience using some of the most sophisticated medical devices in health care gives him insight and expertise to drive progress for the benefit of patients and consumers."

Paul Harari, M.D., FASTRO; Chair, ASTRO Board of Directors 2018-2019; Jack Fowler Professor and Chairman of Human Oncology, University of Wisconsin School of Medicine and Public Health

 

For more information: www.astro.org

 

Related Content

Of all the buzzwords one would have guessed would dominate 2020, few expected it to be “virtual”. We have been virtualizing various aspects of our lives for many years, but the circumstances of this one has moved almost all of our lives into the virtual realm.

Getty Images

Feature | Radiology Education | September 18, 2020 | By Jef Williams
Of all the buzzwords one would have guessed would dominate 2020, few expected it to be “virtual”.
Change Healthcare announced innovative new artificial intelligence (AI) models, trained by expert physicians, which extract meaningful diagnostic information from text in EHRs. The first application of this technology will be within the InterQual AutoReview solution, which automates medical necessity reviews using real-time data from EHRs.
News | Artificial Intelligence | September 14, 2020
September 14, 2020 — Change Healthcare announced innovative new...
The National Imaging Informatics Course-Radiology (NIIC-RAD) Term 1 will be held online September 28 - October 2, 2020. NIIC-RAD is made possible through a partnership between the Radiological Society of North America (RSNA) and the Society for Imaging Informatics in Medicine (SIIM)

Getty Images

News | Radiology Education | September 11, 2020
September 11, 2020 — The...
The Radiological Society of North America (RSNA) has launched its fourth annual artificial intelligence (AI) challenge, a competition among researchers to create applications that perform a clearly defined clinical task according to specified performance measures. The challenge for competitors this year is to create machine-learning algorithms to detect and characterize instances of pulmonary embolism.

Getty Images

News | Artificial Intelligence | September 11, 2020
September 11, 2020 — The Radiological Society of North America (RSNA...
Acquisition accelerates Radiology Partners’ mission to transform radiology, offer unparalleled clinical value and service at scale and further elevate the role of radiologists within the healthcare field

Getty Images

News | Radiology Business | September 10, 2020
September 10, 2020 — Radiology Partners (RP), a leading ra
The world market for artificial intelligence (AI)-based clinical applications for use in medical imaging is set to reach almost $1.5 billion by 2024 despite a slower-than-expected uptake of these products and the impact of the COVID-19 pandemic.
Feature | Artificial Intelligence | September 09, 2020 | Sanjay M Parekh, Ph.D.
Change Healthcare Enterprise Imaging and Change Healthcare Cardiology Hemo now available to Vizient’s diverse provider membership at enhanced savings
News | Enterprise Imaging | September 09, 2020
September 9, 2020 — Change Healthcare announced that it has been awarded two multi-year contracts with ...
While AJR articles were more frequently unfunded, and Radiology articles were more often funded, citation rate was not different between funded vs. unfunded; moreover, funding was not significantly associated with citations

Note: Except where otherwise indicated, data are number (%) of research articles. aSignificance lost after adjustment for multiple testing using false-positive rate control. bStatistically significant. cApplies to Radiology and European Radiology articles only. Courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Radiology Education | September 04, 2020
September 4, 2020 — According to ARRS' Americ